Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Pollard

Obstetrics & Gynecology Cleveland, OH Medical Doctor

NPI 1184792525 CMS profile 326522

2500 Metrohealth Dr, Cleveland, OH 44109

Open in the dashboard

General payments

$16,220

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Pollard of Cleveland, OH is reported in the CMS Open Payments database as having received $16,220 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,115 18
2024 General $1,691 14
2023 General $912 10
2022 General $1,571 12
2021 General $246 3
2020 General $496 4
2019 General $3,189 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Pollard
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Robert Pollard were reported at $8,115. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Robert Pollard Obstetrics & Gynecology median Middle half National median
2019 $3,189 $172 $62–$391 $163
2020 $496 $94 $36–$222 $114
2021 $246 $136 $42–$369 $132
2022 $1,571 $160 $50–$433 $149
2023 $912 $169 $56–$423 $160
2024 $1,691 $152 $50–$371 $164
2025 $8,115 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $8,717 22 payments
  2. Caldera Medical, Inc $3,815 12 payments
  3. Boston Scientific Corporation $884 10 payments
  4. Northgate Technologies, Inc. $600 1 payment
  5. Medtronic, Inc. $591 7 payments
  6. Axonics Modulation Technologies, Inc. $523 6 payments
  7. Coloplast Corp $319 3 payments
  8. Medtronic USA, Inc. $166 2 payments
  9. Davol Inc. $158 1 payment
  10. Bluewind Medical $123 2 payments
  11. Other $323 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,608 52 payments
  2. Education $4,500 3 payments
  3. Travel and Lodging $3,479 10 payments
  4. Consulting Fee $3,460 3 payments
  5. Gift $172 2 payments
Products named General payments · program years 2019–2025
  1. DAVINCI XI $4,500 3 payments
  2. Da Vinci Surgical System $4,217 19 payments
  3. Desara $3,815 12 payments
  4. Vertessa $2,714 2 payments
  5. Axonics $399 5 payments
  6. INTERSTIM $319 4 payments
  7. Advantage System $282 3 payments
  8. LigaSure $272 3 payments
  9. Bulkamid $267 4 payments
  10. Upsylon $252 2 payments
  11. Other $1,277 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

211

Median for Obstetrics & Gynecology: 65

Drug cost

$27,868

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

63.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 17 $15,319
Premarin Estrogens, Conjugated Brand 17 $6,483
Solifenacin Succinate Generic 58 $2,387
Oxybutynin Chloride Er Oxybutynin Chloride Brand 51 $1,826
Estradiol Generic 19 $1,134
Estradiol (Once Weekly) Estradiol Brand 13 $595
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 20 $113
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $10

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$8,183

Medicare's payments for the services billed

Medicare patients

48

Average age 75

Services billed

131

48 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 56%
Diabetes 29%
Cancer 23%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record